Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.
Together, they discuss Rosana and Marty's recent publication regarding a virus-like element in our genome known as LINE-1. LINE-1, part of our "dark genome," was ignored as junk DNA for years, but is increasingly recognized to contribute to the pathology of autoimmunity, cancer, neurodegeneration, and aging. Rosana and Marty discuss how the discovery was made as well as how Rome Therapeutics is developing a platform to target LINE-1 and other factors that are part of the "dark genome" for the treatment of disease.
Additional reading:
The Cost Disease in Healthcare
Journal Club: How to Win an Evolutionary Arms Race
The Google Maps Moment in (Modeling) Biology
Journal Club: Bioengineering Birth
The Story of Schizophrenia
Food as Medicine
Journal Club: Decoding Developmental Disorders
Health—at What Price?
Journal Club: Defeating Type 1 Diabetes
We, the Patients
Journal Club: Architecting an Aggressive Cancer
The Thermodynamics of Life
Journal Club: From Insect Eyes to Nanomaterials
It's Time to Build in Healthcare: COVID-19, Innovation, and What Comes Next
Journal Club: Reversing Parkinson's with New Neurons
The Biology of Pain
Journal Club: Super-Scaling COVID-19 Testing with DNA Sequencing
Biology by Design
Journal Club: Turning a Toxin into a Genome Editing Tool
Going Back to the Workplace in a Pandemic
Create your
podcast in
minutes
It is Free